Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
It has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.06 Increased by +14.29% | -0.05 Decreased by -20.00% |
| Feb 15, 24 | -0.04 Increased by +52.94% | -0.08 Increased by +50.00% |
| Nov 9, 23 | -0.01 Increased by +85.71% | -0.08 Increased by +87.50% |
| Aug 9, 23 | -0.06 Increased by +25.00% | -0.07 Increased by +14.29% |
| May 11, 23 | -0.07 Increased by 0.00% | -0.07 |
| Feb 16, 23 | -0.09 Decreased by -112.50% | -0.08 Decreased by -6.25% |
| Nov 10, 22 | -0.07 Increased by 0.00% | -0.09 Increased by +22.22% |
| Aug 11, 22 | -0.08 Increased by +11.11% | -0.09 Increased by +11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.00 B Increased by +N/A% | -723.11 K Increased by +78.78% | Decreased by -0.07% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -2.87 M Increased by +27.63% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -2.87 M Increased by +14.60% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -3.00 M Decreased by -44.08% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -3.41 M Increased by +4.81% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by -100.00% | -3.97 M Increased by +7.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by -100.00% | -3.36 M Decreased by -1.69 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 4.03 B Increased by +N/A% | -2.08 M Increased by +30.22% | Decreased by -0.05% Decreased by N/A% |